While transcription of NRP1 in melanoma cells is barely detectable due to the action of SOX10/miR-338, this downregulation loses its effect in response to targeted therapy, allowing for NRP1 upregulation and drug resistance formation [200]. Here, NRP1 is linked to melanoma.